Antiangiogenic Therapy for Glioma

Overview

Journal J Signal Transduct

Date 2012 Jul 26

PMID 22830012

Citations 17

Authors

Valentina Cea

Carlo Sala

Chiara Verpelli

Affiliations

Soon will be listed here.

Abstract

Currently, antiangiogenic agents are routinely used for the treatment of patients with glioma. However, despite advances in pharmacological and surgical therapy, glioma remains an incurable disease. Indeed, the formation of an abnormal tumor vasculature and the invasion of glioma cells along neuronal tracts are proposed to comprise the major factors that are attributed to the therapeutic resistance of these tumors. The development of curative therapeutic modalities for the treatment of glioma requires further investigation of the molecular mechanisms regulating angiogenesis and invasion. In this review, we discuss the molecular characteristics of angiogenesis and invasion in human malignant glioma, we present several available drugs that are used or can potentially be utilized for the inhibition of angiogenesis in glioma, and we focus our attention on the key mediators of the molecular mechanisms underlying the resistance of glioma to antiangiogenic therapy.

Citing Articles

Mocetinostat as a novel selective histone deacetylase (HDAC) inhibitor in the promotion of apoptosis in glioblastoma cell line C6 and T98G.

Khathayer F, Mikael M Res Sq. 2024; .

PMID: 38645087 PMC: 11030514. DOI: 10.21203/rs.3.rs-4170668/v1.

Caveolin-1 promotes tumor cell proliferation and vasculogenic mimicry formation in human glioma.

Chen W, Cheng X, Wang X, Hu W, Wang J, Liao C Braz J Med Biol Res. 2021; 54(10):e10653.

PMID: 34287575 PMC: 8289350. DOI: 10.1590/1414-431X2020e10653.

The Role of VEGF Receptors as Molecular Target in Nuclear Medicine for Cancer Diagnosis and Combination Therapy.

Maslowska K, Halik P, Tymecka D, Misicka A, Gniazdowska E Cancers (Basel). 2021; 13(5).

PMID: 33802353 PMC: 7959315. DOI: 10.3390/cancers13051072.

Overexpression of HOXC10 promotes angiogenesis in human glioma via interaction with PRMT5 and upregulation of VEGFA expression.

Tan Z, Chen K, Wu W, Zhou Y, Zhu J, Wu G Theranostics. 2018; 8(18):5143-5158.

PMID: 30429891 PMC: 6217061. DOI: 10.7150/thno.27310.

Long non-coding RNA HOTAIR enhances angiogenesis by induction of VEGFA expression in glioma cells and transmission to endothelial cells via glioma cell derived-extracellular vesicles.

Ma X, Li Z, Li T, Zhu L, Li Z, Tian N Am J Transl Res. 2017; 9(11):5012-5021.

PMID: 29218099 PMC: 5714785.

References

Vredenburgh J, Desjardins A, Herndon 2nd J, Dowell J, Reardon D, Quinn J . Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007; 13(4):1253-9. DOI: 10.1158/1078-0432.CCR-06-2309. View

Castellino R, Durden D . Mechanisms of disease: the PI3K-Akt-PTEN signaling node--an intercept point for the control of angiogenesis in brain tumors. Nat Clin Pract Neurol. 2007; 3(12):682-93. DOI: 10.1038/ncpneuro0661. View

Shepherd F, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V . Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the.... J Clin Oncol. 2002; 20(22):4434-9. DOI: 10.1200/JCO.2002.02.108. View

Kuo T, Kubota T, Watanabe M, Furukawa T, Kase S, Tanino H . Site-specific chemosensitivity of human small-cell lung carcinoma growing orthotopically compared to subcutaneously in SCID mice: the importance of orthotopic models to obtain relevant drug evaluation data. Anticancer Res. 1993; 13(3):627-30. View

Jin Y, Li J, Tang L, Chen J, Feng Z, Liu Y . Protein expression and significance of VEGF, EGFR and MMP-9 in non-small cell lung carcinomas. Asian Pac J Cancer Prev. 2011; 12(6):1473-6. View

Duda D, Cohen K, Scadden D, Jain R . A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc. 2007; 2(4):805-10. PMC: 2686125. DOI: 10.1038/nprot.2007.111. View

Bernhard E . Interventions that induce modifications in the tumor microenvironment. Cancer Radiother. 2011; 15(5):376-82. DOI: 10.1016/j.canrad.2011.01.007. View

Kim K, Li B, Winer J, Armanini M, Gillett N, PHILLIPS H . Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362(6423):841-4. DOI: 10.1038/362841a0. View

Raymond E, Dahan L, Raoul J, Bang Y, Borbath I, Lombard-Bohas C . Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):501-13. DOI: 10.1056/NEJMoa1003825. View

10.

Stupp R, Hegi M, Neyns B, Goldbrunner R, Schlegel U, Clement P . Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010; 28(16):2712-8. DOI: 10.1200/JCO.2009.26.6650. View

11.

Neyns B, Sadones J, Chaskis C, Dujardin M, Everaert H, Lv S . Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J Neurooncol. 2010; 103(3):491-501. DOI: 10.1007/s11060-010-0402-7. View

12.

Reardon D, Fink K, Mikkelsen T, Cloughesy T, ONeill A, Plotkin S . Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008; 26(34):5610-7. DOI: 10.1200/JCO.2008.16.7510. View

13.

Lin E, Nguyen A, Russell R, Pollard J . Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001; 193(6):727-40. PMC: 2193412. DOI: 10.1084/jem.193.6.727. View

14.

Holbeck S . Update on NCI in vitro drug screen utilities. Eur J Cancer. 2004; 40(6):785-93. DOI: 10.1016/j.ejca.2003.11.022. View

15.

Cai W, Wu Y, Chen K, Cao Q, Tice D, Chen X . In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res. 2006; 66(19):9673-81. DOI: 10.1158/0008-5472.CAN-06-1480. View

16.

Takahashi M, Matsui A, Inao M, Mochida S, Fujiwara K . ERK/MAPK-dependent PI3K/Akt phosphorylation through VEGFR-1 after VEGF stimulation in activated hepatic stellate cells. Hepatol Res. 2003; 26(3):232-236. DOI: 10.1016/s1386-6346(03)00112-8. View

17.

Kindler H, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H . Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010; 28(22):3617-22. PMC: 2917317. DOI: 10.1200/JCO.2010.28.1386. View

18.

Shelton L, Mukherjee P, Huysentruyt L, Urits I, Rosenberg J, Seyfried T . A novel pre-clinical in vivo mouse model for malignant brain tumor growth and invasion. J Neurooncol. 2010; 99(2):165-76. DOI: 10.1007/s11060-010-0115-y. View

19.

Raithatha S, Muzik H, Rewcastle N, Johnston R, Edwards D, Forsyth P . Localization of gelatinase-A and gelatinase-B mRNA and protein in human gliomas. Neuro Oncol. 2001; 2(3):145-50. PMC: 1920497. DOI: 10.1093/neuonc/2.3.145. View

20.

Kamba T, McDonald D . Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007; 96(12):1788-95. PMC: 2359962. DOI: 10.1038/sj.bjc.6603813. View